select members of leadership, the Board

Selecta Biosciences (now merged with Larimar Therapeutics) is a clinical-stage biotechnology company focused on developing tolerogenic therapies that mitigate unwanted immune responses. The company's proprietary ImmTOR platform utilizes biodegradable nanoparticles to induce antigen-specific immune tolerance, potentially enhancing the efficacy and safety of biologics and gene therapies. Their lead program, SEL-212, is a combination of a pegylated uricase enzyme and ImmTOR designed for the treatment of chronic refractory gout. By addressing the challenge of anti-drug antibodies, Selecta aims to enable re-dosing of life-saving gene therapies and improve outcomes for patients with rare and autoimmune diseases.